FLT3 and acute myeloid leukemia: In the phase 1/2 CHRYSALIS study, gilteritinib was well tolerated and induced antileukemic activity at doses ≥80 mg/day in patients with relapsed/refractory (R/R) FLT3‐mutated (FLT3mut+) AML.18